While a move towards more reliable P2Y12 inhibitors used in combination with a DOAC is likely in the complex setting of PCI, Professor Storey also invites caution. Find out why.
Alternatively login via
Inflammatory bowel disease assessment tools
Hereditary ATTR amyloidosis
Optimising anti-TNF treatment using biosimilars
Chronic Lymphocytic Leukaemia (CLL)
Anticoagulation Therapy for Stroke Prevention
Back to epgonline.org